KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Abbott Laboratories (ABT) Asset Writedowns and Impairment (2016)

Abbott Laboratories' Asset Writedowns and Impairment history spans 1 years, with the latest figure at $947.0 million for Q3 2016.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to $947.0 million in Q3 2016 year-over-year; TTM through Sep 2016 was $947.0 million, a N/A change, with the full-year FY2016 number at $947.0 million, changed N/A from a year prior.
Asset Writedowns and Impairment hit $947.0 million in Q3 2016 for Abbott Laboratories.
Over the last five years, Asset Writedowns and Impairment for ABT hit a ceiling of $947.0 million in Q3 2016 and a floor of $947.0 million in Q3 2016.